Will ALAB's FY2026 full-year revenue exceed $1.5B?

Achieving $1.5B in FY2026 requires ~76% YoY growth on $852.5M. Q1 guidance midpoint of $291.5M annualizes to $1.17B — well short of $1.5B. To reach $1.5B, the remaining Q2-Q4 quarters must average ~$403M each. That requires significant acceleration from Q1's ~$291M — roughly 38% growth over the remaining quarters. Scorpio X ramp in H2 2026 is the most plausible catalyst for this acceleration, but it's in preproduction as of Q4 2025. Even with a strong Scorpio X ramp and continued Aries/Taurus growth, $400M+ quarterly revenue by Q4 2026 requires near-perfect execution. The deceleration trend (Q/Q: 20% → 17% → 6-10%) works against this target.

The math is demanding. Q1 at $291M → Q2 at $320M → Q3 at $380M → Q4 at $510M to reach $1.5B. That requires 75% growth from Q1 to Q4, which is unrealistic even with Scorpio X. A more realistic scenario: Q1 $295M, Q2 $325M, Q3 $365M, Q4 $415M = $1.4B. This would still be excellent growth (~64% YoY) but misses the $1.5B threshold. The $1.5B mark seems to require analyst consensus to be already pricing in very strong Scorpio X contribution, which contradicts the 'preproduction' status.

The key question is whether Scorpio X can drive a meaningful revenue inflection in H2 2026. If Scorpio X follows the Scorpio P trajectory (exceeded 15% of revenue in its first full year), and the overall TAM is expanding, $1.5B is achievable but requires: (1) Q1 beat above $295M, (2) Q2 at ~$330M, (3) H2 with significant Scorpio X contribution pushing to $435M+ per quarter. This is the bull case and requires the narrative to be validated by execution. The 45% probability reflects that this is plausible but requires above-median execution on multiple dimensions simultaneously.

The deceleration trend is real and structural, not just conservative guidance. Q/Q growth going from 20% to 17% to 6-10% suggests the underlying demand growth rate is normalizing. If Q/Q growth averages 10% for Q2-Q4 (which is optimistic given the trend), we get: Q1 $295M, Q2 $325M, Q3 $357M, Q4 $393M = $1.37B. Even at 12% average Q/Q growth: Q1 $295M, Q2 $330M, Q3 $370M, Q4 $414M = $1.41B. Reaching $1.5B requires Q/Q growth re-accelerating to 15%+ average, which contradicts the deceleration trend.

There's genuine uncertainty about whether Scorpio X can break the deceleration trend. If Scorpio X introduces a step-function in revenue (similar to how Scorpio P exceeded expectations), it could drive Q/Q growth back above 15%. The NVLink Fusion opportunity adds another potential catalyst. However, these are future events with low predictability. The 40% reflects meaningful upside optionality from Scorpio X while acknowledging the base case of continued deceleration falls short of $1.5B.

The market likely needs $1.5B+ to maintain ALAB's current multiple, which means this question tests whether the stock can sustain its valuation. The math requires significant H2 acceleration. Analyst consensus estimates (not available from our analysis but implied by the guidance trajectory) probably target $1.3-1.4B for FY2026. Beating consensus by $100M+ requires a product cycle surprise. Possible with Scorpio X but not the base case.

$1.5B needs ~76% YoY growth. Q1 guidance implies ~60-70% growth rate, decelerating. Unless Scorpio X creates a significant step-function in H2, the company will likely reach $1.3-1.4B — strong but below $1.5B. Scorpio X is the swing factor but it's still in preproduction.

The deceleration from 20% Q/Q to 6-10% is significant. Even with recovery to 12-13% Q/Q in later quarters, the math falls short of $1.5B. This threshold is aspirational for FY2026 given the current trajectory. More likely a 2027 target.

The Scorpio X ramp and NVLink Fusion opportunity provide legitimate upside optionality that could push revenue toward $1.5B. But both require successful execution on tight timelines. The base case ($1.3-1.4B) is strong growth but misses the threshold. 40% probability accounts for the optionality while respecting the deceleration trend.